Implications of ABCG2 Expression on Irinotecan Treatment of Colorectal Cancer Patients: A Review.

ABSTRACT: One of the main chemotherapeutic drugs used on a routine basis in patients with metastatic colorectal cancer ((m)CRC) is the topoisomerase-1 inhibitor, irinotecan. However, its usefulness is limited by the pre-existing or inevitable development of resistance. The ATP-binding cassette (ABC) transporter ABCG2/breast cancer resistance protein (BRCP) through its function in xenobiotic clearance might play an important role in irinotecan resistance. With a goal to evaluate the clinical significance of ABCG2 measurements, we here review the current literature on ABCG2 in relation to irinotecan treatment in CRC patients. Few studies have evaluated the association between ABCG2 gene or protein expression and prognosis in CRC patients. Discordant results were reported. The discrepancies might be ex

SUBMITTER: Nielsen DL 

PROVIDER: S-EPMC5618575 | biostudies-literature | 2017 Sep

REPOSITORIES: biostudies-literature